# A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

> **NCT07670416** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 300 (estimated)

## Conditions studied

- Obesity
- Overweight
- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **COMBINATION_PRODUCT:** Enicepatide
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT07670416
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-03
- **Primary completion:** 2028-02-24
- **Final completion:** 2028-03-15
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670416, "A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07670416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*